(19)
(11) EP 2 142 544 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.07.2013 Bulletin 2013/27

(45) Mention of the grant of the patent:
22.05.2013 Bulletin 2013/21

(21) Application number: 08742864.5

(22) Date of filing: 11.04.2008
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 35/00(2006.01)
 A61K 31/519(2006.01)
(86) International application number:
PCT/US2008/004807
(87) International publication number:
WO 2008/127712 (23.10.2008 Gazette 2008/43)

(54)

PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER

PYRIDO [2,3-D]PYRIMIDIN-7-ONVERBINDUNGEN ALS INHIBITOREN VON PI3K-ALPHA ZUR BEHANDLUNG VON KREBS

COMPOSÉS PYRIDO [2, 3-D]PYRIMIDIN-7-ONE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-ALPHA POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 11.04.2007 US 911160 P

(43) Date of publication of application:
13.01.2010 Bulletin 2010/02

(73) Proprietor: Exelixis, Inc.
South San Francisco, CA 94080 (US)

(72) Inventors:
  • BUHR, Chris A.
    Redwood City, California 94061 (US)
  • WANG, Longcheng
    Palo Alto, California 94306 (US)

(74) Representative: Main, Malcolm Charles 
Murgitroyd & Company Immeuble Atlantis 55 Allee Pierre Ziller
06560 Valbonne - Sophia Antipolis
06560 Valbonne - Sophia Antipolis (FR)


(56) References cited: : 
WO-A-96/34867
WO-A-2008/021389
WO-A1-2008/032162
 WO-A-2005/105801
WO-A1-2007/044698
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).